Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287336 · ClinicalTrials.gov registry record · Phase 2
Prevention of Postpartum Hemorrhage With Tranexamic Acid
A Phase 2 study of Postpartum Hemorrhage, sponsored by George Washington University.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03287336 is a Phase 2 study of Postpartum Hemorrhage that has completed, run by George Washington University. The registered enrollment target is 43 participants, below the 201-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03287336, a Phase 2 study of Postpartum Hemorrhage, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
Postpartum hemorrhage is a significant contributor to maternal morbidity and mortality and is worldwide. TXA has recently been proven to reduce mortality when given to women in setting of diagnosed PPH. US obstetricians and anesthesiologists are hesitant to use TXA in the peripartum period especially for prevention of PPH due to uncertainty of an optimal dose and safety profile. The purpose of this study is to characterize the pharmacokinetics of TXA when given prophylactically at time of delivery. In addition investigators will determine the pharmacodynamics of TXA in the peripartum period.
Conditions Studied
Interventions
- DRUG Tranexamic Acid
Study Locations (1)
District of Columbia
- James Slota - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03287336
The ClinicalTrials.gov registry entry for NCT03287336 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (79% lower). The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic Acid is the first listed.
NCT03287336 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03287336 about?
NCT03287336 is a clinical study titled "Prevention of Postpartum Hemorrhage With Tranexamic Acid". Postpartum hemorrhage is a significant contributor to maternal morbidity and mortality and is worldwide. TXA has recently been proven to reduce mortality when given to women in setting of diagnosed PPH. US obstetricians and anesthesiologists are hesitant to use TXA in the peripartum period especiall...
What is the current status of trial NCT03287336?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-01-02. Estimated completion is 2023-09-30.
What conditions does trial NCT03287336 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage.
What interventions are being tested in trial NCT03287336?
The interventions under investigation include: Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT03287336?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03287336 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
RECRUITING · Phase 3
-
Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping
COMPLETED · NA
-
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
COMPLETED · Phase 3
-
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
COMPLETED · Phase 1
-
Prophylactic Methylergonovine for Twin Cesarean
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.